2010•Chongqing Yike Daxue xuebaoRequires access

FAT regiment for patients with relapsed,refractory acute leukemia

Yun Hua Luo

Open publisher page 0 citations

Abstract

Objective:To observe the therapeutic effects and side effects of FAT (fludarabine,cytarabin,and topotecan)regimen for relapsed or refractory acute leukemia.Methods:The regiment consisted of Flu 25 mg/ (m2·d)iv 30 min,from dl to d5;Ara-C 1.0 or 2 g/ (m2·d)iv 4 h,from dl to d5,and Top 1.2 mg/(m2·d)iv 2h,form d1 to d3. G-CSF was to employ from WBC1.0×109/L until the WBC 4×109/L .9 cases of refractory or relapsed acute leukemia were treated with this regimen.Results:In all the 9 cases of leukemia,6 cases achieved the complete remission (6/9),1 case had achieved partly remission and 2 cases had no response .The main toxicities were myelosupression,fever,diarrhea and slight hepatic injury .Conclusion:FAT regiment shows favorable outcome for refractory or relapsed acute leukemia,and side effects can be tolerance .It can be employed for the patients with refractory or relapsed acute leukemia who had no response to the first line regimen or other salvage regimens and get a chance for further hematopoietic stem cell transplantation.

About this research paper

What this paper is about

Objective:To observe the therapeutic effects and side effects of FAT (fludarabine,cytarabin,and topotecan)regimen for relapsed or refractory acute leukemia.Methods:The regiment consisted of Flu 25 mg/ (m2·d)iv 30 min,from dl to d5;Ara-C 1.0 or 2 g/ (m2·d)iv 4 h,from dl to d5,and Top 1.2 mg/(m2·d)iv 2h,form d1 to d3. G-CSF was to employ from WBC1.0×109/L until the WBC 4×109/L .9 cases of refractory or relapsed acute leukemia were treated with this regimen.Results:In all the 9 cases of leukemia,6 cases achieved the complete remission (6/9),1 case had achieved partly remission and 2 cases had no response .The main toxicities were myelosupression,fever,diarrhea and slight hepatic injury .Conclusion:FAT regiment shows favorable outcome for refractory or relapsed acute leukemia,and side effects can be tolerance .It can be employed for the patients with refractory or relapsed acute leukemia who had no response to the first line regimen or other salvage regimens and get a chance for further hematopoietic stem cell transplantation.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To observe the therapeutic effects and side effects of FAT (fludarabine,cytarabin,and topotecan)regimen for relapsed or refractory acute leukemia.Methods:The regiment consisted of Flu 25 mg/ (m2·d)iv 30 min,from dl to d5;Ara-C 1.0 or 2 g/ (m2·d)iv 4 h,from dl to d5,and Top 1.2 mg/(m2·d)iv 2h,form d1 to d3. G-CSF was to employ from WBC1.0×109/L until the WBC 4×109/L .9 cases of refractory or relapsed acute leukemia were treated with this regimen.Results:In all the 9 cases of leukemia,6 cases achieved the complete remission (6/9),1 case had achieved partly remission and 2 cases had no response .The main toxicities were myelosupression,fever,diarrhea and slight hepatic injury .Conclusion:FAT regiment shows favorable outcome for refractory or relapsed acute leukemia,and side effects can be tolerance .It can be employed for the patients with refractory or relapsed acute leukemia who had no response to the first line regimen or other salvage regimens and get a chance for further hematopoietic stem cell transplantation.

Key concepts: Refractory (planetary science), Medicine, Acute leukemia, Internal medicine, Gastroenterology, Regimen, Leukemia, Fludarabine

Related papers

Back to paper searchBrowse research topicsOriginal source
FAT regiment for patients with relapsed,refractory acute leukemia — Research Paper | ScholarLens